Events

Info day about the Breakthrough Energy Catalyst Fund
JAN
Tue
25
15:00 - 16:00

This was 3 years ago

Location

online

Programmes
Climate, Energy, Mobility

The European Commission has joined forces with the Breakthrough Energy Fund to stimulate investments in emerging climate projects in the EU. The first call for proposals (RFP) has now been launched and projects from the following four domains are invited to submit proposals

  • Clean hydrogen
  • Direct air capture
  • Sustainable aviation fuel
  • Long duration energy storage

The evaluation process will be ongoing until 2027 so there is no particular deadline. The first round of project assessments will be from 13 May 2022 onwards. More information can be found here.

For those who are interested don’t forget to note down 25 January in your agenda as they will hold a webinar to answer all your questions. You can fill in this registration form if you want to take part.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.